We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-2.98%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.33B
AUM Growth
-$428M
Cap. Flow
-$106M
Cap. Flow %
-2.44%
Top 10 Hldgs %
30.21%
Holding
157
New
4
Increased
80
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$22.8M
2
XLO icon
Xilio Therapeutics
XLO
+$20.3M
3
AURA icon
Aura Biosciences
AURA
+$18M
4
CMPX icon
Compass Therapeutics
CMPX
+$17.7M
5
AGL icon
Agilon Health
AGL
+$10.2M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$49M
2
ALLK
Allakos
ALLK
+$32.4M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$26.3M
4
BOLT icon
Bolt Biotherapeutics
BOLT
+$20.9M
5
OSH
Oak Street Health, Inc.
OSH
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.41%
2 Consumer Staples 1.28%
3 Industrials 0.73%
4 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGL icon
1
Agilon Health
AGL
$1.53B
$202M 4.68%
299,800
+16,800
+6% +$10.2M
HUM icon
2
Humana
HUM
$43.7B
$162M 3.74%
349,000
+7,000
+2% +$3.1M
ALGN icon
3
Align Technology
ALGN
$12.1B
$131M 3.04%
200,000
– –
ISRG icon
4
Intuitive Surgical
ISRG
$127B
$129M 2.99%
360,000
– –
PODD icon
5
Insulet
PODD
$11.5B
$123M 2.85%
463,750
+26,184
+6% +$7.6M
UNH icon
6
UnitedHealth
UNH
$376B
$121M 2.78%
240,000
– –
IDXX icon
7
Idexx Laboratories
IDXX
$44.1B
$119M 2.74%
180,000
– –
HCA icon
8
HCA Healthcare
HCA
$87.2B
$116M 2.67%
450,000
– –
ARGX icon
9
argenx
ARGX
$53.4B
$110M 2.55%
315,000
– –
NBIX icon
10
Neurocrine Biosciences
NBIX
$16.8B
$94.1M 2.17%
1,105,000
+53,500
+5% +$4.92M
BPMC
11
DELISTED
Blueprint Medicines
BPMC
$92.1M 2.13%
859,755
+10,096
+1% +$1.06M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.79B
$87M 2.01%
2,646,625
+90,446
+4% +$3.64M
IMCR icon
13
Immunocore
IMCR
$1.72B
$84.6M 1.96%
2,471,555
+26,400
+1% +$956K
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$80.4M 1.86%
746,000
+44,000
+6% +$4.8M
EW icon
15
Edwards Lifesciences
EW
$49.6B
$75.4M 1.74%
582,000
– –
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$2.45B
$74.3M 1.72%
883,921
+82,812
+10% +$6.74M
ZLAB icon
17
Zai Lab
ZLAB
$2.06B
$74.2M 1.71%
1,180,700
+102,950
+10% +$8.73M
BAX icon
18
Baxter International
BAX
$13.5B
$63M 1.46%
733,803
+283,803
+63% +$22.8M
NVAX icon
19
Novavax
NVAX
$1.2B
$60.8M 1.4%
425,000
-30,000
-7% -$5.15M
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$60.2M 1.39%
410,415
+56,901
+16% +$8.83M
PCRX icon
21
Pacira BioSciences
PCRX
$1.04B
$60.2M 1.39%
1,000,000
– –
NVRO
22
DELISTED
NEVRO CORP.
NVRO
$57.9M 1.34%
714,000
+78,300
+12% +$7.85M
EVH icon
23
Evolent Health
EVH
$348M
$56.4M 1.3%
2,038,000
+163,000
+9% +$4.68M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$27.5B
$56.4M 1.3%
332,500
+21,500
+7% +$4M
ACRS icon
25
Aclaris Therapeutics
ACRS
$726M
$56.1M 1.3%
3,861,347
+58,115
+2% +$880K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rock Springs Capital Management held 157 positions worth $4.33B, down 9% from $4.76B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2021 filing shows 4 new, 80 increased, 15 reduced and 21 closed positions. Its largest new stake was Xilio Therapeutics: 85,078 shares worth $19.1M. The largest sale was Teleflex, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2021 buy was Xilio Therapeutics: 85,078 shares worth $19.1M.
  • Rock Springs Capital Management added most to Baxter International in Q4 2021, an estimated $22.8M increase.
  • Rock Springs Capital Management's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Teleflex in Q4 2021, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $4.33B portfolio in Q4 2021.
  • Rock Springs Capital Management opened 4 new positions and closed 21 in Q4 2021.
  • Rock Springs Capital Management's portfolio value fell 9% quarter-over-quarter to $4.33B.

Based on Rock Springs Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.